TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Specialized Palliative Care Team Intervention for Patients With Metastatic Cancer: A Cluster Randomized Trial
Brief Summary: Patients with advanced cancer often have numerous physical and psychological symptoms, which can negatively affect their quality of life. A palliative care team of different health care professionals (including doctors, nurses, social workers and therapists) specializes in treating these symptoms and offers support for patients and their families. However, palliative care teams are currently involved only in the last two months of a patient's life or not at all.

The main purpose of this study is to determine whether, compared to conventional cancer care, early involvement by a specialized symptom control and palliative care team in patients with advanced cancer will be associated with: better quality of life, greater patient and caregiver satisfaction with care, better symptom control, improved communication with healthcare providers and improved caregiver quality of life.


Options:
A: Arm Label: Early Palliative Care Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Arm Label: Conventional Cancer Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Intervention Type: BEHAVIORAL; Name: Early Palliative Care Referral; Assigned to Arm(s): Conventional Cancer Care, Early Palliative Care Referral
B: Arm Label: Usual Care + Transitional Care Model; Type: EXPERIMENTAL; Interventions: Behavioral: Transitional Care Model, Behavioral: Usual care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Transitional Care Model; Assigned to Arm(s): Usual Care + Transitional Care Model | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care, Usual Care + Transitional Care Model
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: OTHER; Interventions: Other: Transition program | Intervention Type: OTHER; Name: Transition program; Assigned to Arm(s): Intervention Group
D: Arm Label: Home-based Palliative Care; Type: EXPERIMENTAL; Interventions: Other: Home-based palliative care | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced usual care | Intervention Type: OTHER; Name: Home-based palliative care; Assigned to Arm(s): Home-based Palliative Care | Intervention Type: OTHER; Name: Enhanced usual care; Assigned to Arm(s): Enhanced Usual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Specialized Palliative Care Team Intervention for Patients With Metastatic Cancer: A Cluster Randomized Trial
Brief Summary: Patients with advanced cancer often have numerous physical and psychological symptoms, which can negatively affect their quality of life. A palliative care team of different health care professionals (including doctors, nurses, social workers and therapists) specializes in treating these symptoms and offers support for patients and their families. However, palliative care teams are currently involved only in the last two months of a patient's life or not at all.

The main purpose of this study is to determine whether, compared to conventional cancer care, early involvement by a specialized symptom control and palliative care team in patients with advanced cancer will be associated with: better quality of life, greater patient and caregiver satisfaction with care, better symptom control, improved communication with healthcare providers and improved caregiver quality of life.


Options:
A: Arm Label: Intervention Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Training Program Intervention | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training Program Intervention; Assigned to Arm(s): Intervention Arm
B: Arm Label: Early Palliative Care Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Arm Label: Conventional Cancer Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Intervention Type: BEHAVIORAL; Name: Early Palliative Care Referral; Assigned to Arm(s): Conventional Cancer Care, Early Palliative Care Referral
C: Arm Label: Clinicians with MI coaching; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing | Arm Label: Wait-list control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Wait-list control | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): Clinicians with MI coaching | Intervention Type: BEHAVIORAL; Name: Wait-list control; Assigned to Arm(s): Wait-list control
D: Arm Label: communication lecture; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: communication lecture | Arm Label: lecture plus CD-ROM; Type: EXPERIMENTAL; Interventions: Behavioral: lecture plus CD-ROM | Intervention Type: BEHAVIORAL; Name: communication lecture; Assigned to Arm(s): communication lecture | Intervention Type: BEHAVIORAL; Name: lecture plus CD-ROM; Assigned to Arm(s): lecture plus CD-ROM

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Specialized Palliative Care Team Intervention for Patients With Metastatic Cancer: A Cluster Randomized Trial
Brief Summary: Patients with advanced cancer often have numerous physical and psychological symptoms, which can negatively affect their quality of life. A palliative care team of different health care professionals (including doctors, nurses, social workers and therapists) specializes in treating these symptoms and offers support for patients and their families. However, palliative care teams are currently involved only in the last two months of a patient's life or not at all.

The main purpose of this study is to determine whether, compared to conventional cancer care, early involvement by a specialized symptom control and palliative care team in patients with advanced cancer will be associated with: better quality of life, greater patient and caregiver satisfaction with care, better symptom control, improved communication with healthcare providers and improved caregiver quality of life.


Options:
A: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: Specialised palliative care (SPC) group; Type: EXPERIMENTAL; Interventions: Other: Specialised palliative care (SPC) | Arm Label: Standard care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Specialised palliative care (SPC); Assigned to Arm(s): Specialised palliative care (SPC) group
C: Arm Label: Early Palliative Care Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Arm Label: Conventional Cancer Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Intervention Type: BEHAVIORAL; Name: Early Palliative Care Referral; Assigned to Arm(s): Conventional Cancer Care, Early Palliative Care Referral
D: Arm Label: Early entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early palliative care intervention | Arm Label: Later entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Later entry group | Intervention Type: BEHAVIORAL; Name: Later entry group; Assigned to Arm(s): Later entry group | Intervention Type: BEHAVIORAL; Name: Early palliative care intervention; Assigned to Arm(s): Early entry group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Ankylosing Spondylitis
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of golimumab in Chinese patients with ankylosing spondylitis


Options:
A: Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Golimumab (placebo group) | Arm Label: Golimumab; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Golimumab | Intervention Type: DRUG; Name: Golimumab (placebo group); Assigned to Arm(s): Placebo
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Etanercept (Enbrel) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Etanercept (Enbrel); Assigned to Arm(s): A | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulphasalazine (SSZ) | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: sulphasalazine (SSZ); Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incidence of Respiratory Illness in Outpatient Healthcare Workers Who Wear Respirators or Medical Masks While Caring for Patients
Brief Summary: Despite widespread use of respiratory protective equipment in the U.S. healthcare workplace, there is very little clinical evidence that respirators prevent healthcare personnel (HCP) from airborne infectious diseases. Scientific investigation of this issue has been quite complicated, primarily because the use of respirators has become "the standard of care" for protection against airborne diseases in some instances, even without sufficient evidence to support their use. The key question remains: How well do respirators prevent airborne infectious diseases? The answer to this important question has important medical, public health, political and economic implications.


Options:
A: Arm Label: N95 Respirator; Type: ACTIVE_COMPARATOR; Interventions: Device: N95 Respirator | Arm Label: Medical/surgical mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Medical/surgical mask | Intervention Type: DEVICE; Name: N95 Respirator; Assigned to Arm(s): N95 Respirator | Intervention Type: DEVICE; Name: Medical/surgical mask; Assigned to Arm(s): Medical/surgical mask
B: Arm Label: Normal recommendations, no mask; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Normal recommendations AND mask; Type: EXPERIMENTAL; Interventions: Other: Surgical facial mask | Intervention Type: OTHER; Name: Surgical facial mask; Assigned to Arm(s): Normal recommendations AND mask
C: Arm Label: Facemask and hand hygiene; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask, Behavioral: 62% Ethyl Alcohol Hand Sanitizer | Arm Label: Facemask only; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Ear Loop Procedure Mask; Assigned to Arm(s): Facemask and hand hygiene, Facemask only | Intervention Type: BEHAVIORAL; Name: 62% Ethyl Alcohol Hand Sanitizer; Assigned to Arm(s): Facemask and hand hygiene
D: Arm Label: Group 1 Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2 Enhanced Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Supplemental training, education and hygiene | Arm Label: Group 3 Chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gluconate, Other: Supplemental training, education and hygiene | Intervention Type: DRUG; Name: Chlorhexidine gluconate; Assigned to Arm(s): Group 3 Chlorhexidine | Intervention Type: OTHER; Name: Supplemental training, education and hygiene; Assigned to Arm(s): Group 2 Enhanced Standard, Group 3 Chlorhexidine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incidence of Respiratory Illness in Outpatient Healthcare Workers Who Wear Respirators or Medical Masks While Caring for Patients
Brief Summary: Despite widespread use of respiratory protective equipment in the U.S. healthcare workplace, there is very little clinical evidence that respirators prevent healthcare personnel (HCP) from airborne infectious diseases. Scientific investigation of this issue has been quite complicated, primarily because the use of respirators has become "the standard of care" for protection against airborne diseases in some instances, even without sufficient evidence to support their use. The key question remains: How well do respirators prevent airborne infectious diseases? The answer to this important question has important medical, public health, political and economic implications.


Options:
A: Arm Label: Normal recommendations, no mask; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Normal recommendations AND mask; Type: EXPERIMENTAL; Interventions: Other: Surgical facial mask | Intervention Type: OTHER; Name: Surgical facial mask; Assigned to Arm(s): Normal recommendations AND mask
B: Arm Label: mouth rinse with antiviral; Type: ACTIVE_COMPARATOR; Interventions: Device: mouthrinse with bêta-cyclodextrin and citrox | Arm Label: mouth rinse without antiviral; Type: PLACEBO_COMPARATOR; Interventions: Device: mouthrinse without bêta-cyclodextrin and citrox | Intervention Type: DEVICE; Name: mouthrinse with bêta-cyclodextrin and citrox; Assigned to Arm(s): mouth rinse with antiviral | Intervention Type: DEVICE; Name: mouthrinse without bêta-cyclodextrin and citrox; Assigned to Arm(s): mouth rinse without antiviral
C: Arm Label: 1; Type: OTHER; Interventions: Other: Control | Arm Label: 2; Type: OTHER; Interventions: Device: Masks | Arm Label: 3; Type: OTHER; Interventions: Device: Masks & hand hygiene | Intervention Type: DEVICE; Name: Masks; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Masks & hand hygiene; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): 1
D: Arm Label: N95 Respirator; Type: ACTIVE_COMPARATOR; Interventions: Device: N95 Respirator | Arm Label: Medical/surgical mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Medical/surgical mask | Intervention Type: DEVICE; Name: N95 Respirator; Assigned to Arm(s): N95 Respirator | Intervention Type: DEVICE; Name: Medical/surgical mask; Assigned to Arm(s): Medical/surgical mask

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incidence of Respiratory Illness in Outpatient Healthcare Workers Who Wear Respirators or Medical Masks While Caring for Patients
Brief Summary: Despite widespread use of respiratory protective equipment in the U.S. healthcare workplace, there is very little clinical evidence that respirators prevent healthcare personnel (HCP) from airborne infectious diseases. Scientific investigation of this issue has been quite complicated, primarily because the use of respirators has become "the standard of care" for protection against airborne diseases in some instances, even without sufficient evidence to support their use. The key question remains: How well do respirators prevent airborne infectious diseases? The answer to this important question has important medical, public health, political and economic implications.


Options:
A: Arm Label: Hypochlorous acid group; Type: EXPERIMENTAL; Interventions: Drug: Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO) | Arm Label: Povidone-iodine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO) | Arm Label: Saline group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO) | Intervention Type: DRUG; Name: Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO); Assigned to Arm(s): Hypochlorous acid group, Povidone-iodine group, Saline group
B: Arm Label: Intervention Nursing Homes; Type: EXPERIMENTAL; Interventions: Other: Prevention of infections program | Arm Label: Usual care Nursing Homes; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Prevention of infections program; Assigned to Arm(s): Intervention Nursing Homes
C: Arm Label: N95 Respirator; Type: ACTIVE_COMPARATOR; Interventions: Device: N95 Respirator | Arm Label: Medical/surgical mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Medical/surgical mask | Intervention Type: DEVICE; Name: N95 Respirator; Assigned to Arm(s): N95 Respirator | Intervention Type: DEVICE; Name: Medical/surgical mask; Assigned to Arm(s): Medical/surgical mask
D: Arm Label: Group 1 Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2 Enhanced Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Supplemental training, education and hygiene | Arm Label: Group 3 Chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gluconate, Other: Supplemental training, education and hygiene | Intervention Type: DRUG; Name: Chlorhexidine gluconate; Assigned to Arm(s): Group 3 Chlorhexidine | Intervention Type: OTHER; Name: Supplemental training, education and hygiene; Assigned to Arm(s): Group 2 Enhanced Standard, Group 3 Chlorhexidine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incidence of Respiratory Illness in Outpatient Healthcare Workers Who Wear Respirators or Medical Masks While Caring for Patients
Brief Summary: Despite widespread use of respiratory protective equipment in the U.S. healthcare workplace, there is very little clinical evidence that respirators prevent healthcare personnel (HCP) from airborne infectious diseases. Scientific investigation of this issue has been quite complicated, primarily because the use of respirators has become "the standard of care" for protection against airborne diseases in some instances, even without sufficient evidence to support their use. The key question remains: How well do respirators prevent airborne infectious diseases? The answer to this important question has important medical, public health, political and economic implications.


Options:
A: Arm Label: RSV vaccine formulation 1 Group; Type: EXPERIMENTAL; Interventions: Biological: RSV vaccine GSK3003895A (formulation 1) | Arm Label: RSV vaccine formulation 2 Group; Type: EXPERIMENTAL; Interventions: Biological: RSV vaccine GSK3003898A (formulation 2) | Arm Label: RSV vaccine formulation 3 Group; Type: EXPERIMENTAL; Interventions: Biological: RSV vaccine GSK3003899A (formulation 3) | Arm Label: Boostrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Boostrix | Intervention Type: BIOLOGICAL; Name: RSV vaccine GSK3003895A (formulation 1); Assigned to Arm(s): RSV vaccine formulation 1 Group | Intervention Type: BIOLOGICAL; Name: RSV vaccine GSK3003898A (formulation 2); Assigned to Arm(s): RSV vaccine formulation 2 Group | Intervention Type: BIOLOGICAL; Name: RSV vaccine GSK3003899A (formulation 3); Assigned to Arm(s): RSV vaccine formulation 3 Group | Intervention Type: BIOLOGICAL; Name: Boostrix; Assigned to Arm(s): Boostrix Group
B: Arm Label: N95 Respirator; Type: ACTIVE_COMPARATOR; Interventions: Device: N95 Respirator | Arm Label: Medical/surgical mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Medical/surgical mask | Intervention Type: DEVICE; Name: N95 Respirator; Assigned to Arm(s): N95 Respirator | Intervention Type: DEVICE; Name: Medical/surgical mask; Assigned to Arm(s): Medical/surgical mask
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: MEDI-534 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: MEDI-534 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: MEDI-534 | Intervention Type: BIOLOGICAL; Name: MEDI-534; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: MEDI-534; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: MEDI-534; Assigned to Arm(s): 3
D: Arm Label: RSV LID ΔM2-2 Vaccine; Type: EXPERIMENTAL; Interventions: Biological: RSV LID ΔM2-2 Vaccine | Arm Label: Placebo Vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Vaccine | Intervention Type: BIOLOGICAL; Name: RSV LID ΔM2-2 Vaccine; Assigned to Arm(s): RSV LID ΔM2-2 Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo Vaccine; Assigned to Arm(s): Placebo Vaccine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy & Cost-Effectiveness of Lactobacillus Reuteri DSM 17938 Administration to Prevent the Risk of Respiratory or Gastrointestinal Infections in Child Day Care Centers: A Randomized, Double Blind, Placebo Control Trial (RDDCT).
Brief Summary: Randomized, doble blind, clinical, controlled trial aimed to investigate the role of Lactobacillus reuteri DSM 17938 in the prevention of gastrointestinal and respiratory tract infections in mexican children who attend day care centers.

Primary Outcome: The primary outcome will be "days with diarrhoea". Secondary Outcomes: a) Days with respiratory tract infections (RTI); b) Days of absences from day care centre; c) Days of antibiotic use; d) Days of medical office visits or emergency visits; and e) Direct and Indirect costs.

Methods: Prospective, randomized, double blind, placebo controlled trial to realize in 260 healthy term infants, born at term (≥36 weeks of gestation), 6 to 36 months old, who will be recruit from Child Care Centers in Mexico and randomly allocated to receive either 1 x 108 colony-forming units of Lactobacillus reuteri DSM 17938 or placebo, each day for 12 weeks, follow up for other additionally 12 weeks of observation. Days with respiratory tract infections (RTI); days of absences from day care centre; days of antibiotic use; days of medical office visits or emergency visits; and direct and Indirect costs will be compare between groups using bi-variate, multiple lineal regression analysis and cost-effectiveness analysis


Options:
A: Intervention Type: DRUG; Name: Micronutrient (Zinc and Iron) fortification; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Pre and Probiotic fortification; Assigned to Arm(s): N/A
B: Arm Label: Lreuteri; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lreuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lreuteri; Assigned to Arm(s): Lreuteri | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: fermented milk; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fermented milk | Arm Label: fermented rice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fermented rice | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: fermented milk; Assigned to Arm(s): fermented milk | Intervention Type: DIETARY_SUPPLEMENT; Name: fermented rice; Assigned to Arm(s): fermented rice
D: Arm Label: Bifidobacterium animalis subsp. lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium animalis subsp. lactis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium animalis subsp. lactis; Assigned to Arm(s): Bifidobacterium animalis subsp. lactis

Answer: B